Chronic Plaque Psoriasis Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Chronic Plaque Psoriasis Treatment Market Trends and Insights

Uptake of High-Efficacy IL-17 and IL-23 Inhibitors

The chronic plaque psoriasis treatment market is benefiting from a higher clinical standard that increasingly emphasizes PASI 90 and PASI 100 responses. In the PSoHO observational study, IL-17A inhibitors achieved PASI 100 in 39.70% of patients and PASI 90 in 55.20% at 24 months, compared with PASI 100 in 32.80% of patients receiving anti-TNFα agents^{[1]BMC Immunology, “Comparative Efficacy and Safety of IL-17 and IL-23 Inhibitors for Moderate-to-Severe Psoriasis in Asian Populations,” BMC Immunology, link.springer.com.}. A 2026 meta-analysis of 32 randomized controlled trials involving nearly 14,000 participants found that IL-17 and IL-23 inhibitors were superior to placebo in Asian populations, with a log odds ratio of 1.40 and a 95% confidence interval of 1.17 to 1.62. These results support broader formulary adoption in markets where evidence in non-Western patient populations influences treatment decisions. Drug-survival evidence also favors newer agents, as bimekizumab, guselkumab, and risankizumab showed lower 2-year discontinuation risk than ustekinumab among bio-experienced patients^{[2]PubMed, “Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis,” JAMA Dermatology, pubmed.ncbi.nlm.nih.gov.}. The chronic plaque psoriasis treatment market, therefore, continues to shift away from older biologic classes, even where those treatments remain important for patients with limited access to newer medicines.

Expansion of Oral Targeted Immunomodulators

Oral therapies are changing the chronic plaque psoriasis treatment market because they can reduce the practical burden of injectable treatment. Johnson & Johnson received FDA approval in March 2026 for icotrokinra, an oral peptide that targets the IL-23 receptor, for adults and adolescents aged 12 years and older with moderate-to-severe plaque psoriasis.^{[3]Johnson & Johnson, “ICOTYDE One-Year Results Confirm Lasting Skin Clearance and Favorable Safety Profile,” Johnson & Johnson, prnewswire.com.} Four Phase 3 ICONIC studies involving 2,500 patients found that 70% achieved an Investigator’s Global Assessment of clear or almost clear skin and 55% achieved PASI 90 at Week 16. The European Medicines Agency recommended marketing authorization for icotrokinra in July 2026, making it the first oral medicine targeting the IL-23 receptor to receive a positive CHMP opinion for plaque psoriasis EMA.^{[4]European Medicines Agency, “First Oral Medicine Targeting Interleukin-23 Receptor Recommended for Plaque Psoriasis,” European Medicines Agency, ema.europa.eu.}Takeda reported that zasocitinib was statistically superior to deucravacitinib in a Phase 3 study during June 2026, with more than half of treated patients achieving PASI 90 TAKEDA. These launches and late-stage programs can bring previously untreated patients into the chronic plaque psoriasis treatment market when injection aversion, perceived safety concerns, or specialty-dispensing requirements had delayed care.

Emerging-Market Biologic and Biosimilar Access

Reimbursement and biosimilar availability are expanding the chronic plaque psoriasis treatment market in emerging economies. China included deucravacitinib in the 2024 National Reimbursement Drug List for moderate-to-severe plaque psoriasis, improving access to an oral TYK2 inhibitor in a large treated population. Biocon Biologics received Japanese approval for its ustekinumab biosimilar in December 2024 and launched the product through Yoshindo in 2025. Samsung Bioepis also received Japanese approval for an ustekinumab biosimilar in December 2025, followed by National Health Insurance listing in May 2026 through NIPRO Corporation. Sun Pharmaceutical launched Ilumya, or tildrakizumab, in India during 2025, introducing an IL-23 inhibitor for Indian dermatologists treating moderate-to-severe plaque psoriasis. LEO Pharma received China’s NMPA approval for Enstilar in April 2026 after a 604-patient Phase 3 study showed superiority over Daivobet ointment, with a commercial launch planned later in 2026. These developments support access across several treatment lines rather than relying only on premium imported biologics.

Pediatric Label Expansion and Age-Appropriate Formulations

Pediatric label expansion adds a long-duration treatment opportunity to the chronic plaque psoriasis treatment market. AbbVie stated that nearly 30% of people who develop psoriasis experience symptoms before age 18, and an estimated 20,000 U.S. children younger than 10 years are diagnosed each year. The FDA approved risankizumab in June 2026 for children aged 6 years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. The approval included a 55 mg prefilled syringe for weight-based dosing in patients below 40 kg. The European Commission also approved risankizumab for pediatric patients aged 6 years and older during June 2026, based on Phase 3 OptIMMize data. Johnson & Johnson received FDA approval for guselkumab in children aged 6 years and older in September 2025, supported by Phase 3 PROTOSTAR data. Earlier access to approved therapies may strengthen continuity of treatment as pediatric patients progress into adult care.

High Biologic Costs and Payer Utilization Controls

High treatment costs and utilization controls can slow the chronic plaque psoriasis treatment market even when advanced therapies show strong clinical outcomes. Commercial payer protocols often require patients to complete several treatment steps before gaining access to newer biologics or oral medicines. A 2025 analysis of 194 U.S. commercial step-therapy protocols found that 99.40% imposed more requirements than clinical guidelines supported, while 68.40% of psoriatic arthritis protocols exceeded guideline recommendations. The same research found that 92% of surveyed physicians reported a negative effect on clinical outcomes from these restrictions. The mismatch can be especially difficult for people with scalp, nail, genital, or palmoplantar disease, where quality-of-life burden can be severe despite limited body surface area. Thirty-eight U.S. states had enacted step-therapy protection laws by 2025, and the proposed Safe Step Act would require payers to respond to exception requests within 24 to 72 hours.

Longitudinal Loss of Response and Treatment Persistence Attrition

Treatment persistence limits the chronic plaque psoriasis treatment market because plaque psoriasis requires ongoing management over many years. In the CorEvitas Psoriasis Registry, failure to maintain the initial response was cited in 51.70% of 159 biologic-switching cases, and 83.00% of switchers had moderate-to-severe disease compared with 26.10% of non-switchers. A Spanish registry reported 10-year first-line biologic persistence of 25.90%, with insufficient efficacy responsible for 51.00% of discontinuations. Switching can preserve patient access to care, but it adds administrative costs and can lead payers to tighten coverage conditions. Patients who become bio-experienced may have fewer suitable treatment options and may show lower response rates to later therapies. The lower discontinuation risk reported for bimekizumab, guselkumab, and risankizumab among bio-experienced patients suggests that persistence is becoming an important point of competition between newer and older biologic classes.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Treatment Modality: Biologic Drugs Lead Revenue While Oral Systemic Drugs Drive Growth

Biologic Drugs held 58.32% of the chronic plaque psoriasis treatment market share within treatment modality revenue in 2025. IL-17 and IL-23 inhibitors have become central options for moderate-to-severe disease because they offer high clearance rates and established long-term use in specialist practice. In network meta-analyses, bimekizumab, ixekizumab, and brodalumab achieved PASI 90 as early as Weeks 6 to 8. Real-world evidence also found favorable drug survival for risankizumab and guselkumab, which supports continued use of IL-23 inhibitors.

Oral Systemic Drugs are forecast to grow at a 14.94% CAGR from 2026 to 2031, the fastest rate among treatment modalities. TYK2 inhibitors and oral IL-23 receptor therapies are the main reasons for this expansion. Icotrokinra’s 2026 approval established a new oral treatment option that aims for efficacy previously associated mainly with injectable biologics. Combination regimens also retain a clinical role for high-impact-site disease and difficult-to-treat presentations.

By Route of Administration: Injectable Therapies Remain Largest While Oral Therapies Gain Ground

Injectable therapies accounted for 57.62% of the chronic plaque psoriasis treatment market share by route of administration in 2025. Their position reflects the long-standing role of subcutaneous IL-17 and IL-23 biologics in moderate-to-severe plaque psoriasis. Guselkumab and risankizumab showed strong drug survival among bio-naive patients in Danish real-world evidence.

The Oral route is forecast to expand at an 11.55% CAGR from 2026 to 2031. Icotrokinra demonstrated that an oral therapy can approach the performance range of advanced injectable treatments, with 55% of patients reaching PASI 90 at Week 16 in its Phase 3 program. Oral options can reduce concerns around injection aversion and may simplify treatment initiation for patients and practices. The Topical route remains important by prescription volume but contributes less revenue because of its lower unit price.

By Disease Severity: Moderate Disease Is the Largest Segment While Severe Disease Grows Fastest

Moderate disease held 42.38% of the chronic plaque psoriasis treatment market share by disease severity in 2025. This segment includes many patients who did not achieve acceptable control with topical or conventional systemic treatment and meet clinical thresholds for biologic initiation. High-impact-site involvement can create substantial burden even when total body surface area is low. Aetna’s 2025 Medicaid policy recognized crucial body-area involvement as a coverage criterion independent of body surface area percentage.

The Severe segment is forecast to grow at an 11.56% CAGR from 2026 to 2031. Reclassification of high-impact-site disease is contributing to the expansion of the severe treatment population in some settings. Patients with severe disease may also switch biologics more often, creating several treatment episodes across the care journey. 

By Patient Type: Adults Account for Most Revenue While Geriatric Patients Expand Fastest

Adults captured 82.32% of the chronic plaque psoriasis treatment market share by patient type in 2025. This position reflects the concentration of diagnosed psoriasis among people aged 25 to 60 years and the established availability of biologics for this group. Adult treatment is supported by defined monitoring protocols and clinician familiarity with several biologic classes. 

The Geriatric segment is forecast to grow at an 11.78% CAGR through 2031. Population aging in North America, Europe, and Japan is increasing the relevance of psoriasis treatment in people with polypharmacy and multiple chronic conditions. Drug selection in older adults must account for cardiovascular conditions, renal function, and infection risk. A 15-year multicenter cohort study reported that TNF inhibitors had the highest hepatitis B virus reactivation risk among the biologic classes assessed, while IL-23 inhibitors had the lowest risk and the longest time to reactivation.

By Distribution Channel: Hospital Pharmacies Lead While Online Pharmacies Expand Fastest

Hospital Pharmacies held 41.32% of the chronic plaque psoriasis treatment market share by distribution channel in 2025. Injectable biologics often require injection training, prior-authorization documentation, laboratory follow-up, and coordination with dermatology services. These needs favor hospital-affiliated and specialty pharmacy settings with existing clinical infrastructure. 

Online Pharmacies are forecast to grow at a 12.31% CAGR from 2026 to 2031. Digital fulfillment, mail-order coverage models, and the rise of oral treatment are reducing some of the friction associated with specialty dispensing. Manufacturers are also testing direct patient-support pathways where conventional coverage processes delay access. 

Geography Analysis

North America held 38.98% of the chronic plaque psoriasis treatment market share in 2025. The region benefits from high biologic penetration, a dense specialist network, and insurance systems that eventually authorize advanced therapy for many eligible patients. UnitedHealthcare’s 2026 criteria included icotrokinra, risankizumab, guselkumab, secukinumab, deucravacitinib, and preferred adalimumab biosimilars as coverage options.

Europe is the second-largest contributor to the chronic plaque psoriasis treatment market, led by Germany, France, the United Kingdom, Italy, and Spain. Germany’s Arzneimittel-Atlas identified psoriasis among the 6 drug categories associated with the strongest statutory health-insurance spending growth during 2024.

Asia-Pacific is forecast to grow at an 11.67% CAGR from 2026 to 2031, the fastest rate among geographic segments. China, Japan, India, South Korea, and Australia are the central markets for this expansion. China is improving access through reimbursement updates and local regulatory approvals, including NMPA approval of Enstilar in April 2026.